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Objectives
Bayesian estimation of missing resource use data and
expected costs in the ASTER trial of endosonographic
staging followed by surgical staging if negative (ES),
compared with surgical staging alone (SS), in candidates
for lung cancer surgery.
To assess how covariates, that are included in the
model to justify a “missing at random” assumption,
affect estimates of expected costs.
Methods
ASTER was a prospective, international, open-label, ran-
domised-controlled study, with a trial-based economic
analysis over 6 months. Due to delays in starting the
health economic study, resource use data were collected
prospectively for the second half of the study only.
Although resource use data could be ascertained retro-
spectively, some items were difficult to ascertain once
patients had been discharged from the trial centre. A
Bayesian parametric model was developed to estimate
missing resource use items and expected costs. Missing
resource use data were modelled using Binomial, Pois-
son, over-dispersed equivalents of these, or using a hur-
dle count model if only a proportion of the patients had
the event (e.g. chemotherapy). Covariates considered
were randomisation group, centre, age, sex and stage of
lung cancer. The total expected cost was calculated as
the sum of the resource use component-specific
expected costs for each randomisation group.
Results
ES was more sensitive, resulted in fewer futile thoraco-
tomies and had better utility during staging than SS. All
patients had initial diagnostic tests and management
recorded but subsequent resource use components were
missing for 10-20% of cases, and only 71% had complete
resource use data. Using the complete cases only, the
mean 6 month cost of ES was £10,614 (£8515, £13,073)
per patient versus £11,788 (£9053, £15,321) for SS,
mean difference £1174 (-£948, £3912), so that ES was
cheaper but with considerable uncertainty in these esti-
mates. The Bayesian model aimed to recapture power
lost due to missing data and when randomisation group
was the only covariate, point estimates were reduced by
5% and posterior standard deviations were reduced by
10% compared with complete case analysis. Inclusion of
other covariates resulted in small subgroups, imprecise
point estimates for covariates and a resulting increase in
the posterior variance for expected costs.
Conclusions
Resource use in patient groups is highly variable and
trials are rarely powered for secondary outcomes that
drive costs, so that inclusion of many parameters in a
Bayesian analysis may result in inefficient estimation.
Covariate selection should consider both the missing
data mechanism and efficiency.
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